Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Lybeck

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Translational Oncology|November 13, 2014
Rewriting the epigenetic code for tumor resensitization: a reviewBryan Oronsky, Neil Oronsky, Jan Scicinski, et al.
Expert Opinion on Drug Delivery|April 26, 2020
Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mixScott Caroen, Bryan Oronsky, Corey Carter, et al.
Oncotarget|January 28, 2016
Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapyBryan Oronsky, Corey Carter, Anna Scicinska, et al.
Clinical Reviews in Allergy & Immunology|February 20, 2021
A Review of Persistent Post-COVID Syndrome (PPCS)Bryan Oronsky, Christopher Larson, Terese C Hammond, et al.
Journal of Cancer|August 1, 2022
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)Bryan Oronsky, Nacer Abrouk, Scott Caroen, et al.
Neoplasia (New York, N.Y.)|December 12, 2017
Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A ReviewBryan Oronsky, Patrick Ma, Tony R Reid, et al.
Anti-Cancer Agents in Medicinal Chemistry|August 8, 2014
Follow the ATP: tumor energy production: a perspectiveBryan T Oronsky, Neil Oronsky, Gary R Fanger, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2017
Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and managementBryan Oronsky, Scott Caroen, Arnold Oronsky, et al.
Oncotarget|March 24, 2016
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesCorey A Carter, Karen Zeman, Regina M Day, et al.
Expert Review of Hematology|April 28, 2017
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injuryPedro Cabrales, Scott Caroen, Arnold Oronsky, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Translational Oncology|November 13, 2014
Rewriting the epigenetic code for tumor resensitization: a reviewBryan Oronsky, Neil Oronsky, Jan Scicinski, et al.
Expert Opinion on Drug Delivery|April 26, 2020
Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mixScott Caroen, Bryan Oronsky, Corey Carter, et al.
Oncotarget|January 28, 2016
Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapyBryan Oronsky, Corey Carter, Anna Scicinska, et al.
Clinical Reviews in Allergy & Immunology|February 20, 2021
A Review of Persistent Post-COVID Syndrome (PPCS)Bryan Oronsky, Christopher Larson, Terese C Hammond, et al.
Journal of Cancer|August 1, 2022
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)Bryan Oronsky, Nacer Abrouk, Scott Caroen, et al.
Neoplasia (New York, N.Y.)|December 12, 2017
Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A ReviewBryan Oronsky, Patrick Ma, Tony R Reid, et al.
Anti-Cancer Agents in Medicinal Chemistry|August 8, 2014
Follow the ATP: tumor energy production: a perspectiveBryan T Oronsky, Neil Oronsky, Gary R Fanger, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2017
Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and managementBryan Oronsky, Scott Caroen, Arnold Oronsky, et al.
Oncotarget|March 24, 2016
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesCorey A Carter, Karen Zeman, Regina M Day, et al.
Expert Review of Hematology|April 28, 2017
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injuryPedro Cabrales, Scott Caroen, Arnold Oronsky, et al.
Pageof 3